Inactive Instrument

Highlights GB Sciences, Inc. Other OTC

Equities

GBLX

US3615441090

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 20	CI
GB Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
GB Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-14	CI
Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of Lethbridge	23-07-11	CI
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-03	CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-09	CI
Gb Sciences, Inc. Receives Positive Preclinical Results in an Interim Report from Its Study Using Preclinical Zebrafish Models of Stress At the National Research Council of Canada	22-10-24	CI
GB Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-11	CI
GB Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-30	CI
Gb Sciences, Inc. Showcases Its Pharos™ Drug Discovery Platform At the 2Nd Alcor Drug Discovery Platform Summit	22-05-12	CI
GB Sciences, Inc. to Begin Dosage Study for its Novel Parkinson's Disease Formulations at the University of Lethbridge	22-04-12	CI
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations as Demonstrated in New Research Article	22-03-29	CI
GB Sciences, Inc. Announces Grant of U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis	22-03-01	CI
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-11	CI
An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. for $8 million.	22-01-10	CI
Gb Sciences Reports Positive Results from Study of its Potential Treatment for Cytokine Release Syndrome	21-12-06	CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-15	CI
GB Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation	21-09-14	CI
Gb Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2021	21-07-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GB Sciences, Inc. Other OTC

Equities

GBLX

US3615441090

Highlights

Filters